NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 3.59 against a street estimate of 3.60 — a miss of 0.3%.
with an average price target of ₹777.50.
| Document | Date |
|---|---|
| Q1 FY27 earnings call SUDEEP PHARMA LIMITED – Q1 FY27 EARNINGS SUMMARY HEADLINE NUMBERS • Revenue from operations: INR 158.3 crores in Q1 FY27, up 27% YoY (from INR 124.9 | 2026-08-11 |
| Quarterly results · Q1 FY27 SUDEEP PHARMA LIMITED - Q1 FY2026-27 FINANCIAL SUMMARY HEADLINE NUMBERS • Consolidated Revenue from Operations (Q1 FY27): Rs. 15,827.05 lakhs vs Rs. | 2026-08-04 |
| Investor presentation SUDEEP PHARMA LIMITED – Q1 FY27 INVESTOR SUMMARY HEADLINE NUMBERS • Revenue from Operations Q1FY27: Rs. 158.3 Cr, up 27% YoY (Q1FY26: Rs. 124.9 Cr) | 2026-08-04 |
| Investor presentation | 2026-08-04 |
| Annual report FY2026 SUDEEP PHARMA LIMITED – ANNUAL REPORT 2025-26 SUMMARY HEADLINE NUMBERS • Revenue from operations: `642.3 crores (+28% YoY) • EBITDA: `221.9 crores, | 2026-07-10 |
| Q4 FY26 earnings call SUDEEP PHARMA LIMITED – Q4 & FY26 SUMMARY HEADLINE NUMBERS • Revenue from operations FY26: INR 642.3 crores (up 27.9% YoY from INR 501.9 crores in F | 2026-05-28 |
| Investor presentation · Q4 FY26 SUDEEP PHARMA LIMITED – Q4FY26 INVESTOR SUMMARY HEADLINE NUMBERS • FY26 Revenue from Operations: Rs. 642.3 crore, up 28% YoY (FY25: Rs. 502.0 crore) | 2026-05-21 |
| Quarterly results · Q4 FY26 SUDEEP PHARMA LIMITED – DOCUMENT SUMMARY HEADLINE NUMBERS • Full Year FY2026 Revenue from Operations: Rs. 64,225.80 lakhs (vs Rs. 50,199.92 lakhs in | 2026-05-21 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹1.50 / share ex-date Jul 23, 2026 | 2026-07-23 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Sudeep Pharma Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.